HKIC, a Hong Kong government-owned fund, agreed to invest in BioMap, a startup biotech company. Financial terms were not disclosed. “We intend to leverage Hong Kong’s international status, favourable financial policies, globally aligned IP and data regulations to garner trust from multinational clients, and maintain our competitive edge amid international competition. In addition, Hong Kong has a rich pool of interdisciplinary AI and biotechnology talent, and an innovative academic environment,” Wei Liu, BioMap Co-Founder and CEO.